PharmaShots | Incisive News in 3 Shots

Subscribe Now

Alagille Syndrome

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

November 16, 2021

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

November 16, 2021

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

Mirum Reports Six Years Results of LIvmarli (maralixibat) for the Treatment of Alagille Syndrome

November 16, 2021

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

Celltrion's Regdanvimab Receives the EC's Approval for the Treatment of COVID-19

November 16, 2021

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with...

September 29, 2021

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with Alagille Syndrome

Mirum's Livmarli (maralixibat) Receives US FDA's Approval as the First Approved Therapy for Cholestatic Pruritus in Patients with...

September 29, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us